Category Archives: Nano Medicine

Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients

PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 24, 2022. The focus of this years summit is From Hope to Product The Brilliant Prospect in Nanomedicine and Related Fields.

Dr. Noam Emanuel, Chief Scientific Officer of PolyPid, will present the abstract, From Bench to Bedside: D-PLEX100 Limits AMR Occurrence in Randomized Double-Blind Phase 2 Trial in Colorectal Surgery Patients, demonstrating D-PLEX100 as a safe and effective surgical site infection prevention agent without affecting the incidence of postoperative colonization by multi drug resistant organisms. Dr. Emanuels presentation will be available on https://www.polypid.com/ following the summit.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPids proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Corporate Contact:

PolyPid, Ltd.Dikla Czaczkes AkselbradEVP & CFOTel: +972-747195700

Investor Contact:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com

Media Contact:Nechama FeuersteinFINN Partners 551-444-0784Nechama.Feuerstein@finnpartners.com

View post:
PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine - GlobeNewswire

In 2019, Ikea announced it had developed curtains that it claimed could break down common indoor air pollutants. The secret, it said, was the fabrics special coating. What if we could use textiles to clean the air? asked Ikeas product developer, Mauricio Affonso, in a promotional video for the Gunrid curtains.

After explaining that the coating was a photocatalyst (similar to photosynthesis, found in nature), Affonso is shown gazing up at the gauzy curtains while uplifting music plays. Its amazing to work on something that can give people the opportunity to live a healthier life at home.

Puzzled by these claims how could a mineral coating clean the air? Avicenn, a French environmental nonprofit organisation, investigated. Independent laboratory tests of the Gunrid textile reported that samples contained tiny particles of titanium dioxide (TiO2) a substance not normally toxic but which can be possibly carcinogenic if inhaled, and potentially in other forms which supposedly gives self-cleaning properties to things such as paint and windows when exposed to sunlight.

These tiny particles, or nanoparticles, are at the forefront of materials science. Nanoparticles come in all shapes spheres, cubes, fibres or sheets but the crucial thing is their size: they are smaller than 100 nanometres (a human hair is approximately 80,000nm thick).

Many nanoparticles exist in nature. Nano-hairs make a geckos feet sticky, and nano-proteins make a spiders silk strong. But they can be manufactured, and because they are so small, they have special properties that make them attractive across a range of endeavours not just to companies such as Ikea. In medicine, they can transport cancer drugs directly into tumour cells, and nanosilver is used to coat medical breathing tubes and bandages. Nanos could direct pesticides to parts of a plant, or release nutrients from fertilisers in a more controlled manner.

They also have more mundane uses. Synthetic nanos are added to cosmetics and food. Nanosilver is used in textiles, where it is claimed to give antibacterial properties to plasters, gym leggings, yoga mats and period pants.

But scientists such as those at Avicenn are concerned that when these household items get washed, recycled or thrown away, synthetic nanos are released into the environment making their way into the soil and sea in ways that are still not understood. Some scientists believe nanoparticles could pose an even greater threat than microplastics.

Synthetic nano particles of plastic have been found in the ocean and in ice on both poles. Nanoparticles from socks and sunscreen have been found to pollute water, and certain nanos have been shown to negatively affect marine wildlife including fish and crustaceans. As with antibiotics, resistance to antimicrobial nanosilver can develop silver-tolerant soil bacteria have now been found.

Little is known even about where nanoparticles are, let alone their effects on the environment. As they are so tiny, most experiments are conducted in labs, and it can be hard to pin down where they are applied.

The main problem with these substances is that we cannot measure them we know they are there but theyre so tiny theyre difficult to detect, which is why you dont hear as much about them, says Nick Voulvoulis, professor of environmental technology at Imperial College London.

He worries about the uncontrolled use of nanos in consumer products. If nanos are used properly in applications that are useful or beneficial, thats justified, but if they are used anywhere and everywhere because they have certain properties, thats crazy.

Synthetic nanoparticles are not inherently harmful. Like their natural cousins, many are metal-based, but they can be made of any substance. Crucially, unlike chemical compounds, they cannot be dissolved. Their tiny size gives them, paradoxically, an enormous surface area, which makes them behave differently to non-nano versions of the same material. It can make them more mobile, more reactive and potentially more toxic, depending on shape, size, type, how a substance is released into the environment and its concentration.

And released into the environment they are, on a massive scale. According to Avicenn, the release of nanos is most likely during manufacture or disposal, but it can also happen when items are washed which is known to occur with fabrics containing nanosilver. Sewage systems cannot trap them and they end up in the ocean: the OECD says even advanced wastewater-treatment plants cannot deal with nanoparticles.

From a health perspective, inhalation is the most harmful route of exposure to nanos such as TiO2 for factory workers and consumers. Avicenns tests concluded that the average particle size was 4.9nm, and all 300 particles analysed were below the official nano threshold of 100nm.

Ikea insisted its own tests showed the TiO2 particles were properly bound to the fabric and pose no risk to customers, and said it took workers safety extremely seriously. The firm has not referred to them as nanoparticles, and said that once integrated into textile surfaces there was no good standard method to measure the particle size distribution of a material, acknowledging that EU definitions of nanomaterials were under review.

We recognise that the tests and measurements of nano-particles are complex, especially for materials containing particles that tend to form agglomerates, it said.

As for Ikeas curtains shedding TiO2 nanoparticles when washed or discarded, Ikea said it was confident that the treatment is properly bound to the fabric, and therefore we do not see a risk of inhaling the treatment, but acknowledged that as with any textile, parts of the textile can come off during use or washing.

Many nanos do not persist for long in the environment. However, because they are consistently being discharged, levels remain fairly constant. Nanos are pseudo-persistent because they degrade quite quickly but they keep entering the environment, Voulvoulis says.

His main concern is whether nanos become carriers for other compounds, a subject of scientific debate. In 2009, Spanish scientists suggested nanos could bind to and transport toxic pollutants, and possibly be toxic themselves by generating reactive free radicals. If other toxic pollutants latch on to nanos surfaces, they argued, marine plants and animals could absorb them more easily.

Other scientists suggest the opposite: that organic matter in sewage coat nanoparticles, rendering them less active. And others fear nanos could trigger toxic cocktail effects making them more harmful in combination than individual substances would be separately.

So far, synthetic nanomaterials are relatively dispersed in the sea, and unlikely to significantly affect marine animals, says Dr Tobias Lammel of Gothenburg University, who has studied copper nanos. But he warns: Its possible that the concentration of some manufactured nanomaterials in the marine environment will increase It is important to keep an eye on this.

Given the huge question marks, Avicenn wants more stringent regulations on nanos, and more caution in product design. Companies are eager to sell innovative and fancy products, but they must thoroughly assess their benefits-risks balance at each step of the life-cycle of the products, says Mathilde Detcheverry, Avicenns policy manager.

From August, the EU will ban use of TiO2 nanos in food (where it is called E171) and the European Commission recently announced that 12 nanomaterials would soon be prohibited in cosmetics.

Detcheverry says: As scientific knowledge about the environmental and health impacts of engineered nanos such as silver and titanium dioxide advances, we need to make sure nanos are only allowed for specific and essential uses in order to minimise any adverse effects at the source and [ensure they are] not released uncontrollably.

Two years after the release of Ikeas Gunrid curtains, Avicenn tried to buy more for further tests, but they had been withdrawn from sale.

Ikea told the Guardian that Gunrid remained safe to use as a traditional curtain but it was withdrawn because the functionality was not as effective as expected. If thats true for example, that despite TiO2 having proven photocatalytic properties and being used in self-cleaning and air-purifying products, its efficacy on curtains could be localised and not powerful then at the very least Ikeas experience suggests nanoparticles benefits may not outweigh the potential and frequently unknown risks, Detcheverry says.

Nanoparticles are often promoted as silver bullets against pollution or bacteria, she says, but we must make sure that the cure is not worse than the disease.

Gunrid was just one product of many thousands that use nanoparticles. As Ikeas Affonso says in the video: Whats so great about Gunrid is that this technology could be applied to any textile.

This article was amended on 26 April 2022 to correct the spelling of Gothenburg.

Read the original post:
Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian

The Global Nanocapsules Market to reach at an estimated value of USD$ 5,982.01 Million by 2029 and grow at a CAGR of 8.75% in the forecast period of 2022 to 2029.

The most reliable Nanocapsules Market report gives market analysis by taking into account market structure along with forecast of the various segments and sub-segments of the Healthcare industry. An exhaustive analysis of factors influencing the investment is also provided in this report which forecasts impending opportunities for the businesses and develops the strategies to improve return on investment (ROI). The data and the information concerning the Healthcare industry are derived from consistent sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the market experts.

To prosper in this competitive market place, businesses are highly benefited if they adopt innovative solutions such as Nanocapsules Market research report. A number of estimations and calculations have been executed in this market report by assuming definite base year and the historic year. The market document also provides the knowledge of all the drivers and restraints which are derived through SWOT analysis. Nanocapsules report considers various factors that have great effect on the growth of business which includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the Healthcare industry.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanocapsules-market .

According to the market report analysis, Nanopharmacology is defined as a new branch of pharmacology that deals with the application of nanotechnology in the field of nanomedicine. This is a potential step towards prevention and curing of disease by using molecular knowledge about human body and molecular tools. Nanopharmacology studies the interaction between nanoscale drugs and proteins such as RNA, DNA, and cells & tissues.

Some of most important key factors driving the growth of the Global Nanocapsules Market are rise in the incidences of chronic diseases worldwide, growing pharmaceutical industry, rise in the demand for nanocapsules, rise in the demand from the end user industry, increase in the investment and research focus by highly developed countries such as the U.S. and Germany and rise in the implementation of partnership and research collaborations.

The Global Nanocapsules Market is segmented on the basis of Polymer Type, Application, Therapy Area, Route of Administration and Region.

Based on the Polymer Type, the nanocapsules market is segmented into natural polymers and synthetic polymers.

On the basis of Application, the nanocapsules market is segmented into pharmaceutical, cosmetic and others.

On the basis of Therapy Area, the nanocapsules market is segmented into oncology, pain management, endocrinology and others.

Based on the Route of Administration, the nanocapsules market is segmented into parenteral route and oral route.

In terms of the geographic analysis, North America dominates the nanocapsules market due to rise in the demand for nanocapsules, rise in the demand from the end user industry and rise in the implementation of partnership and research collaborations in this region. APAC is the expected region in terms of growth in nanocapsules market due to increase in the opportunities for life science functions of nanocapsules in this region.

Access Complete Report Here: https://www.databridgemarketresearch.com/reports/global-nanocapsules-market .

Global Nanocapsules Market Objectives:

1 To provide detailed information regarding key factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the Nanocapsules Market

2 To analyze and forecast the size of the Nanocapsules Market, in terms of value and volume

3 To analyze opportunities in the Nanocapsules Market for stakeholders and provide a competitive landscape of the market

4 To define, segment, and estimate the Nanocapsules Market based on deposit type and end-use industry

5 To strategically profile key players and comprehensively analyze their market shares and core competencies

6 To strategically analyze micromarkets with respect to individual growth trends, prospects, and contribution to the total market

7 To forecast the size of market segments, in terms of value, with respect to main regions, namely, Asia Pacific, North America, Europe, the Middle East & Africa, and South America

8 To track and analyze competitive developments, such as new product developments, acquisitions, expansions, partnerships, and collaborations in the Nanocapsules Market

Top Leading Key Manufacturers are: BioDelivery Sciences International, Inc., PitchBook Data, Camurus AB, Carlina Technologies, Cerulean Pharma, Gamma Capital, LOral, Nano Green Sciences Inc., NanoSphere Health Sciences, PlasmaChem GmbH and SINTEF. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Nanocapsules in these regions, from 2013 to 2029 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

Get a TOC of Global Nanocapsules Market Report 2022 @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nanocapsules-market .

Global Nanocapsules Market: Table of Contents

1 Report Overview 2022-2029

2 Global Growth Trends 2022-2029

3 Competition Landscape by Key Players

4 Global Nanocapsules Market Analysis by Regions

5 Global Nanocapsules Market Analysis by Type

6 Global Nanocapsules Market Analysis by Applications

7 Global Nanocapsules Market Analysis by End-User

8 Key Companies Profiled

9 Global Nanocapsules Market Manufacturers Cost Analysis

10 Marketing Channel, Distributors, and Customers

11 Market Dynamics

12 Global Nanocapsules Market Forecasts 2022-2029

13 Research Findings and Conclusion

14 Methodology and Data Source

Get Our More Trending Research Report Here:

1 Global Glucosamine Market Industry Trends and Forecast to 2029

2 Global Hurler-Scheie Syndrome Market Industry Trends and Forecast to 2029

3 Global Inguinal Hernia Market Industry Trends and Forecast to 2029

4 Global Latex Examination Glove Market Industry Trends and Forecast to 2029

5 Global Minimally Invasive Gastrointestinal Surgical Systems Market Industry Trends and Forecast to 2029

6 Global Ophthalmic Ultrasound Imaging Systems Market Industry Trends and Forecast to 2029

7 Global Peutz-Jeghers Syndrome Market Industry Trends and Forecast to 2029

8 Global Polyisoprene (PI) Surgical Gloves Market Industry Trends and Forecast to 2029

9 Global Postoperative Nausea and Vomiting Treatment Market Industry Trends and Forecast to 2029

10 Global Postpartum Hemorrhage Treatment Devices Market Industry Trends and Forecast to 2029

11 Global Sarilumab Market Industry Trends and Forecast to 2029

12 Global Scalpels Market Industry Trends and Forecast to 2029

13 Global Seminoma-associated Paraneoplastic Syndrome Market Industry Trends and Forecast to 2029

14 Global Stilboestrol Market Industry Trends and Forecast to 2029

15 Global X-linked Adrenoleukodystrophy Market Industry Trends and Forecast to 2029

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [emailprotected]

Link:
Nanocapsules Market Growth to Remain Strong as Suggested by the Report with Key Players Camurus, Carlina Tech, Cerulean Pharma | Forecast to 2029 -...

Introduction

Recently nanoscale drugs become an area of intense novel drug research.1,2 Several nanocarriers, including liposomes, have been utilized for cancer therapies.3,4 Among these, liposomes have attracted the most attention because of their potency of side effects,5 prolonged the retention-time for encapsulated payloads in cancer cells,6 effectively resolving some of the problems of off-target effects of anticancer drugs by improving the pharmacokinetic profiles and pharmacological properties of several agents.7,8

Clinical trials are the most effective strategy for evaluating the efficacy of a drug on a specific disease9,10 and are a critical step in the successful development of more effective drugs.11 Thus, exploring clinical trials, especially analyzing registered clinical trials, has become an important facet of research to help future clinical practice. ClinicalTrials.gov is a public trial registry provided by the US National Library of Medicine and the US Food and Drug Administration. Zarin et al12 postulated that the number of clinical trials in ClinicalTrials.gov accounted for more than 80% of all studies in the World Health Organizations International Clinical Trials Registry Platform. This proportion will likely expand with further implementation of the Food and Drug Administration Amendments Act (FDAAA 801), which expands the scope of mandatory clinical trial registration.13 Moreover, a joint statement from all International Committee of Medical Journal Editors (ICMJE) member journals indicated that clinical trials must be publicly registered in trials registries before they are considered for publication. Therefore, to better evaluate the breadth of liposome treatments for pediatric cancers, we performed a cross-sectional study to investigate the characteristic of registered trials in ClinicalTrials.gov regarding liposomes in childrens anticancer therapy.

A cross-sectional, descriptive study of clinical trials for LCAT registered on the ClinicalTrials.gov database was conducted. The trials were obtained from ClinicalTrials.gov using the advanced search function with the search term cancer for condition or disease and the term liposome for Other terms on December 30, 2021. All of the identified clinical trials were assessed to obtain records of all studies. Intervention and observation studies were all included. We used the age field as a filter, and we included trials explicitly designed for the child (birth 17 years of age). Next, we manually reviewed all of the trials and selected those using liposomal drugs for childrens anticancer therapy. Trials utilizing non-liposomal drugs were excluded. The following information and data were extracted: registered number, title, study type, conditions, interventions, locations, start date, the status of the trial, study results, study samples, participant ages, primary sponsor, location, primary purpose, phases of each trial, allocation, intervention model, masking and intervention. All trials were then further subclassified according to their study type. We used descriptive statistics to characterize trial categories. Frequencies and percentages were provided for categorical data. All analyses were performed using Microsoft Excel (Microsoft Office Excel 2010, Microsoft Corporation).

The initial search identified 1552 clinical trials on liposomes in cancer therapy registered on the ClinicalTrials.gov database through December 30, 2021. After using the age field (child; birth 17 years of age) as a filter, 352 trials focusing on liposomes in childrens anticancer therapy were included. After carefully reviewing all the information, 278 trials were not liposomal drugs and were excluded. Thus, a total of 74 registered trials focusing on liposomes in childrens anticancer therapy were subsequently included, including four observational studies and 70 intervention trials (Figure 1).

Figure 1 Flowchart of trial selection.

The basic characteristics of the included trials are shown in Table 1. Among the 74 eligible trials, 70 (94.6%) were interventional trials, and the 4 (5.4%) were observational trials. Half of these trials were initiated prior to 2007. Every five years, the number of initiated trials changed a little from 2007 to 2021. Most of the included trials (47.3%) have been completed, although only 23.0% of trials had available results in this database. The sources of funding were indicated for 40.5% of trials. The National Institutes of Health (NIH) was the second-largest contributor, accounting for 36.5% of included trials. North America was the most frequently identified study location (68.9%), followed by Europe (14.9%), Asia (12.2%), and other (4.1%).

Table 1 Characteristics of All Included Trials

Of the four observational trials, two were retrospective, and two trials were prospective. Of the 70 interventional trials, 63 (90.0%) were for treatment, 3 (4.3%) were for supportive care, 2 (2.9%) were for diagnostic, and 2 (2.9%) were for prevention. The allocation concealment was not clear in 48.6% of these studies. 21 (30.0%) trials were randomized, and 15 (21.4%) trials were non-randomized. More than half of the intervention models were single group assignments (52.9%), followed by parallel assignments (22.9%), and unknown (21.4%). Among the 70 interventional trials, the majority of trials (50, 71.4%) were without masking, 13 (18.6%) were with unknown masking, and 7 (10.0%) were with masking (1 single masking, 4 double maskings, and 2 quadruple maskings). 20 (28.6%) were phase 3 trials, 21 (30.0%) were phase 1 trials, and 17 (24.3%) were phase 2 trials. More than half of the trials recruited less than 50 participants, 12 trials (17.1%) recruited 100500 individuals, and 12 trials (17.1%) did not indicate the number of participants. The study design characteristics of interventional trials are displayed in Table 2.

Table 2 Study Design Elements of Interventional Trials (n = 70)

A total of 70 interventional trials investigated 17 liposomal drugs, mainly focused on organic chemicals (43/70, 61.4%). 32 trials (45.7%) investigated liposomal doxorubicin. Of these trials for liposomal drugs, the highest proportion was testing liposomal doxorubicin (45.7%), followed by liposomal vincristine (17.1%) and liposomal cytarabine (5.7%). Three trials investigated liposomal complex compounds, of which two trials were liposomal daunorubicin-cytarabine, and one trial was liposomal doxorubicin-daunorubicin. A summary of studied liposomal drugs for prevention is provided in Table 3.

Table 3 Overview of Drugs for Prevention

A total of 70 interventional trials investigated 17 liposomal drugs for 123 types of cancer. Of these cancers, the highest proportion was leukemia (15.4%), followed by lymphoma (9.8%) and ovarian cancer (8.9%). Detailed data is shown in Figure 2.

Figure 2 Overview cancer types assessed for liposomal treatment for prevention (n = 123). The following cancers appeared only once: advanced cancer, bone cancer, germ cell tumors, glioma, invasive pulmonary aspergillosis, kidney tumor, lung cancer, multiple myeloma, nasopharyngeal carcinoma, pancreatic cancer, pediatric cancer, plasma cell neoplasm, precancerous condition, and prostate cancer.

Liposomes have been extensively investigated for overcoming cancer drug resistance,14 cancer-targeted therapy,15 and as a sustained and controlled release drug delivery system.16 However, liposomes do have limited clinical utility due to properties such as uncontrollable drug release, instability in storage, and insufficient drug loading.17 Specifically, due to their small aqueous internal volumes, liposomes have a relatively low encapsulation efficacy for water-soluble drugs.18 Meanwhile, large-scale liposomes production with low batch-to-batch differences is a challenge for the industry, which ultimately delays the clinical translation of new products.19 In addition, recruitment of children is a persistent challenge for researchers seeking to include these populations in clinical trials.20 First, societal concerns and parental emotional involvement can act to delay or prevent certain types of paediatric research.20,21 Second, medical ethics and clinical trial design for children need further refinement.22 Thus, the number of trials of liposomes in childrens anticancer therapy has not increased significantly over time and clinical trials focusing on liposomes account for only about 4.77% (74/1552) of clinical trials on liposomes in cancer therapy. Liposomally-delivered drugs have predominantly been organic chemicals (43/70, 61.4%). For example, 32 trials (45.7%) investigated liposomal doxorubicin. These results were following previous literature reports on the efficacy of delivering doxorubicin this way. To enhance the solubility of a hydrophobic substance, lipid-based drug delivery systems, especially liposomes, are among the best candidates.2325

In this study, the highest proportion of cancer type for prevention in a children was leukemia (15.4%), and the highest proportion of liposomal drug was in liposomal doxorubicin (45.7%), followed by liposomal vincristine (17.1%) and liposomal cytarabine (5.7%). For decades, the standard of care for treating acute myeloid leukemia (AML) has been the combination of a nucleoside analog with an anthracycline.26,27 Vincristine and cytarabine are nucleoside, and doxorubicin is a type of anthracycline. This indicated that liposomal doxorubicin combined with vincristine or cytarabine for childhood leukemia is an important future direction for liposomes in childrens anticancer therapy.

High quality, adequately powered, masked, appropriately sized, and appropriately sized, and randomized clinical trials represent a critical priority for high-quality clinical trials.2830 However, only 30.0% of trials studied here were randomized, and the majority of trials (71.4%) were without masking. Previously, it has been suggested that efficient trial designs are essential for rare malignancies has randomized trials are less feasible.31 To address this, there are multiple strategies for, such using as a Bayesian posterior predictive approach,32 or using complex innovative design,33 a novel multi-arm, multi-stage (MAMS) design.34 Hearn et al35 discussed in depth this issue highlighting the need for decision-makers to avoid adopting entrenched positions about the nature of the trial design.

The authors declare there are no conflicts of interest regarding the publication of this paper.

1. Jiang X, Zheng Y-W, Bao S, et al. Drug discovery and formulation development for acute pancreatitis. Drug Deliv. 2020;27(1):15621580. doi:10.1080/10717544.2020.1840665

2. Guo S, Liang Y, Liu L, et al. Research on the fate of polymeric nanoparticles in the process of the intestinal absorption based on model nanoparticles with various characteristics: size, surface charge and pro-hydrophobics. J Nanobiotechnol. 2021;19(1):32. doi:10.1186/s12951-021-00770-2

3. Qi -S-S, Sun J-H, Yu H-H, Yu S-Q. Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug Deliv. 2017;24(1):19091926. doi:10.1080/10717544.2017.1410256

4. Kim K, Khang D. Past, present, and future of anticancer nanomedicine. Int J Nanomedicine. 2020;15:57195743. doi:10.2147/IJN.S254774

5. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1):2544. doi:10.1517/17425247.5.1.25

6. Suntres ZE. Liposomal antioxidants for protection against oxidant-induced damage. J Toxicol. 2011;2011:152474. doi:10.1155/2011/152474

7. Landi-Librandi AP, Chrysostomo TN, Caleiro Seixas Azzolini AE, Marzocchi-Machado CM, de Oliveira CA, Lucisano-Valim YM. Study of quercetin-loaded liposomes as potential drug carriers: in vitro evaluation of human complement activation. J Liposome Res. 2012;22(2):8999. doi:10.3109/08982104.2011.615321

8. Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics. 2013;5(3):457471. doi:10.3390/pharmaceutics5030457

9. Feizabadi M, Fahimnia F, Mosavi Jarrahi A, Naghshineh N, Tofighi S. Iranian clinical trials: an analysis of registered trials in International Clinical Trial Registry Platform (ICTRP). J Evid Based Med. 2017;10(2):9196. doi:10.1111/jebm.12248

10. Chen L, Su Y, Quan L, Zhang Y, Du L. Clinical trials focusing on drug control and prevention of ventilator-associated pneumonia: a comprehensive analysis of trials registered on ClinicalTrials.gov. Original research. Front Pharmacol. 2019;9. doi:10.3389/fphar.2018.01574

11. Jacobsen PB, Wells KJ, Meade CD, et al. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012;30(20):25162521. doi:10.1200/JCO.2011.39.5186

12. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DAB. Issues in the registration of clinical trials. JAMA. 2007;297(19):21122120. doi:10.1001/jama.297.19.2112

13. Tse T, Williams RJ, Zarin DA. Reporting basic results in ClinicalTrials.gov. Chest. 2009;136(1):295303. doi:10.1378/chest.08-3022

14. Bai F, Yin Y, Chen T, et al. Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer. Int J Nanomedicine. 2018;13:13271339. doi:10.2147/IJN.S150237

15. Riaz MK, Riaz MA, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci. 2018;19(1):195. doi:10.3390/ijms19010195

16. Yue P-J, He L, Qiu SW, et al. OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. Mol Cancer. 2014;13:191. doi:10.1186/1476-4598-13-191

17. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138157. doi:10.1016/j.jconrel.2014.12.030

18. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi:10.1186/1556-276x-8-102

19. Al-Amin MD, Bellato F, Mastrotto F, et al. Dexamethasone loaded liposomes by thin-film hydration and microfluidic procedures: formulation challenges. Int J Mol Sci. 2020;21(5):1611. doi:10.3390/ijms21051611

20. Cunningham-Erves J, Deakings J, Mayo-Gamble T, Kelly-Taylor K, Miller ST. Factors influencing parental trust in medical researchers for child and adolescent patients clinical trial participation. Psychol Health Med. 2019;24(6):691702. doi:10.1080/13548506.2019.1566623

21. Rentea RM, Oyetunji TA, Peter SDS. Ethics of randomized trials in pediatric surgery. Pediatr Surg Int. 2020;36(8):865867. doi:10.1007/s00383-020-04665-5

22. Nicholl A, Evelegh K, Deering KE, et al. Using a Respectful Approach to Child-centred Healthcare (ReACH) in a paediatric clinical trial: a feasibility study. PLoS One. 2020;15(11):e0241764. doi:10.1371/journal.pone.0241764

23. Nik ME, Malaekeh-Nikouei B, Amin M, et al. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma. Sci Rep. 2019;9(1):9527. doi:10.1038/s41598-019-45974-7

24. Laverman P, Boerman OC, Storm G, Oyen WJG. (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx) in glioblastomas and metastatic brain tumours. Br J Cancer. 2002;86(4):659661. doi:10.1038/sj.bjc.6600093

25. Wang G, Wang J, Wu W, Tony To SS, Zhao H, Wang J. Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert Opin Drug Deliv. 2015;12(9):14751499. doi:10.1517/17425247.2015.1021681

26. Chen EC, Fathi AT, Brunner AM. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018;11:34253434. doi:10.2147/OTT.S141212

27. Preisler HD, Anderson K, Rai K, et al. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol. 1989;71(2):189194. doi:10.1111/j.1365-2141.1989.tb04253.x

28. Zwierzyna M, Davies M, Hingorani AD, Hunter J. Clinical trial design and dissemination: comprehensive analysis of ClinicalTrials.gov and PubMed data since 2005. BMJ. 2018;361:k2130. doi:10.1136/bmj.k2130

29. Zhang C, Kwong JSW, Yuan R-X, et al. Effectiveness and tolerability of different recommended doses of PPIs and H(2)RAs in GERD: network meta-analysis and GRADE system. Sci Rep. 2017;7:41021. doi:10.1038/srep41021

30. Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in older persons: advances in diagnosis and treatment. JAMA. 2017;318(12):11611174. doi:10.1001/jama.2017.12067

31. Italiano A, Nanda S, Briggs A, et al. Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: an intra-patient comparative analysis. Cancers. 2020;12(11):3246. doi:10.3390/cancers12113246

32. Dutton P, Love S, Faleti A, Hassan B. The use of Bayesian design in two trials in rare cancers. Trials. 2015;16(Suppl 2):P213. doi:10.1186/1745-6215-16-S2-P213

33. Blagden SP, Billingham L, Brown LC, et al. Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement. Br J Cancer. 2020;122(4):473482. doi:10.1038/s41416-019-0653-9

34. Sydes MR, Parmar MKB, Mason MD, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168. doi:10.1186/1745-6215-13-168

35. Hearn J, Keat N, Law K, Sharpe R. How cancer research UK is adapting to adaptive designs. Trials. 2011;12(Suppl 1):A6. doi:10.1186/1745-6215-12-S1-A6

See the original post here:
Clinical Trial of Liposomes in Children's Anticancer Therapy | IJN - Dove Medical Press

The new report by Expert Market Research titled, Global Advanced Functional Materials Market Report and Forecast 2021-2026, gives an in-depth analysis of the globaladvanced functional materials market, assessing the market based on its type, end-use, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/advanced-functional-materials-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

The growth in the global advanced functional materials market is induced by the medical device technology which is advancing at a rapid pace. With increased focus on imaging techniques, implantable devices, and regeneration technologyin medicine, drug delivery industrial equipment, and biomedical engineering, the adoption of advanced functional materials is increasing rapidly, that aims to augment growth of the market. Advanced functional materials supersede conventional materials by having superior characteristics such as durability, toughness, durability, and elasticity. The advanced functional material industry for low carbon emissions applications is anticipated to be driven by rising lightweight vehicles demandcombined with improved fuel efficiency.

Industry Definition and Major Segments

Usingeffective power and signaltransmission to every object, advanced functional materials serve to minimise total power usage. Thin conductors or interlinks used within advanced functional material-based mini electronics aid in countering signal propagation and power failure concerns associated with large PCBs and thick interconnects.

Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/advanced-functional-materials-market

Based on its types, the market is divided into:

Based on end-use, the market is divided into:

On the basis of region, the market is divided into:

Market Trends

In the years ahead, the manufacturing of lighter weight, handy, and adaptable substrate technological tools will boost adoption ofadvanced functional materials. One of the crucial industry trends in the advanced functional materials marketis the strong market for microelectronics andminiaturisation. The healthcare industry has a huge demand for advanced functional materials. In the industry, nanomaterials are the dominant type of material. The use of nano materials in the nanotechnological sector of the healthcare industry is consistently expanding. Nanomedicine is the use of nanotechnology to diagnose, monitor, deliver drugs, treat, and regulate biological systems. Although, an absence of expansion plans and technological innovation is anticipated to stymie the industrys growth over the forecast period.

Key Market Players

The major players in the market are Morgan Advanced Materials plc, KYOCERA Corporation, Hexcel Corporation, Nanophase Technologies Corporation, KURARAY CO., LTD, Murata Manufacturing Co., Ltd., and Henkel AG & Co. KGaA (OTCMKTS: HENKY), among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

We also provide state-of-the-art procurement intelligence through our platform,https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market intelligence, supply chain intelligence, procurement analytics, and category insights through our thoroughly researched and infallible market reports, production cost reports, price analysis, and benchmarking.

Informes de Expertos (https://www.informesdeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consultancy services to a broad clientele base across Spanish speaking countries. With our primary focus on the Latin America and Spain markets, our research experts provide relevant and actionable insights into the markets and track major trends, economic developments, and global trade data.

Determined to bring client satisfaction, we make sure that our tailored approach meets the clients unique market intelligence requirements. Our syndicated and customized research reports cover a wide spectrum of industries ranging from pharmaceuticals and food and beverage to packaging, logistics, and transportation.

Media Contact

Company Name: EMR Inc.Contact Person: Sofia Williams, Corporate Sales Specialist U.S.A.Email: sales@expertmarketresearch.comToll Free Number: +1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USACity: SheridanState: WyomingCountry: United StatesWebsite:https://www.expertmarketresearch.com

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Visit link:
Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Satellite Bio emerged from stealth today to reveal first-in-kind Tissue Therapeutics, bioengineered tissues that repair, restore or replace critical organ or tissue function.

Satellite Bio has raised $110 million in previously undisclosed Seed and Series A investments. The Series A round was led by aMoon Growth, and included prior seed stage co-lead Lightspeed, aMoon Velocity, Polaris Partners and Polaris Innovation Fund. New Series A investors included Section 32, Catalio Capital Management and Waterman Ventures.

Through the exclusive Satellite Adaptive Tissue (SAT) platform, Satellite Bio selectively programs cells and then assembles them into novel, implantable therapies, called Satellites, which can be introduced to patients to repair, restore or even replace dysfunctional or diseased tissue or organs. Satellites enable full cell function in vivo, overcoming many of the challenges that have hindered prior attempts to restore organ function and change the course of progressive and difficult-to-treat diseases.

Tissue Therapeutics replaces organ and tissue systems that break down during disease progression. This next frontier of regenerative medicine has enormous potential to provide solutions for some of the most elusive diseases, said Dave Lennon, PhD, chief executive officer of Satellite Bio. Our SAT platform can be used with virtually any type of cell across a wide range of clinical applications, enabling the potential to create a broad pipeline of implantable Tissue Therapeutic solutions for patients.

Satellite Bio has an exclusive license to technology originating in the labs of Sangeeta Bhatia, MD, PhD, director, Center for Nanomedicine, Massachusetts Institute of Technology and Christopher Chen, MD, PhD, director, Biological Design Center, Boston University. Building on the work of Dr. Robert Langer and others, they combined more than two decades of collaborative research in tissue technology, biology and bioengineering to create this new class of regenerative medicine called Tissue Therapeutics. The company was founded by Bhatia and Chen, along with Arnav Chhabra, PhD, head, Satellite Bio Platform R&D in Cambridge, MA, in 2020.

Satellite Bio is led by Dave Lennon, PhD, CEO, who most recently served as president of AveXis and Novartis Gene Therapies, where he launched the groundbreaking regenerative medicine Zolgensma, a gene therapy for spinal muscular atrophy. Satellite Bio is also announcing the appointments of Laura Lande-Diner, PhD, chief business officer and Tom Lowery, PhD, chief technology officer to the executive team. Joining Dave and the Satellite Bio team is an experienced and diverse group of advisors and directors.

"aMoon is proud of our continued partnership with Satellite Bio on its inspiring mission to restore hope to patients suffering from severe, life-threatening conditions, said Dr. Yair Schindel, co-founder and managing partner, aMoon Fund. This new wave of Tissue Therapeutics will save patients whose only other hope would be organ transplant or experimental therapies.

About Tissue Therapeutics

Tissue Therapeutics is a new type of regenerative medicine that programs cells and assembles them into Satellites. They can be implanted into patients to restore, repair or replace dysfunctional or diseased tissue or organs away from the affected organ. These Satellites provide the full repertoire of cell function in vivo and provide an entirely new way to restore organ dysfunction and change the course of elusive, life-threatening diseases.

About Our Leadership

Satellite Bio is led by Dave Lennon, PhD, who most recently served as president of AveXis and Novartis Gene Therapies, Lennon also serves as a board member for the Alliance of Regenerative Medicine (ARM). He is joined on the Satellite Bio board and management by a diverse group of experienced investors and leaders, including Chief Business Officer Laura Lande-Diner, PhD, and Chief Technology Officer Tom Lowery, PhD. Lande-Diner, a scientist, innovator and life sciences entrepreneur, brings deep expertise in company creation and early operationalization across technologies and therapeutic areas. Prior to joining Satellite Bio, she was part of the Flagship Pioneering ecosystem where she was on the founding teams of Valo Health, Omega Therapeutics, Inari Agriculture and Epiva/Evelo Biosciences. Lowery brings 15 years of deep experience in product, process and analytical development and engineering, as well as building highly productive technical and operational teams. He was previously chief scientific officer of T2 Biosystems, where he led technology development from inception through regulatory approval and commercialization for seven products.

About Satellite Bio

Satellite Bio is on a journey to treat some of the most elusive diseases known to humankind by pioneering Tissue Therapeutics, an entirely new category of regenerative medicine.

With the first-of-its-kind SAT (Satellite Adaptive Tissues) platform, Satellite Bio can turn virtually any cell type into bioengineered tissues that are integrated into the body to restore natural function. These tissues, called Satellites, can deliver the comprehensive cellular response needed to repair or even replace critical organ functions in patients with diseases caused by the interaction of genetic and environmental factors. The SAT platform is an unprecedented technology with the potential to drive a pipeline of sophisticated cell-based therapeutic solutions that tackle a broad range of elusive diseases.

Satellite Bios quest is as audacious as it is clear: bring new hope to patients and families suffering from elusive diseases. Tissue Therapeutics is how it will deliver on that promiseand why it is deeply committed to leading and realizing the potential of this exciting new frontier in regenerative medicine. For more information, visit satellite.bio.

See the original post here:
Satellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases - Business Wire